×
Acute QT Interval Modifications During Hydroxychloroquine-Azithromycin Treatment in the...
https://doi.org/10.1016/j.mayocp.2020.05.005
Mayo Clinic Proceedings; Voisin O, Lorc'h EL et. al.

Aug 5th, 2020 - Among candidate drugs to treat coronavirus disease 2019 (COVID-19), the combination of hydroxychloroquine (HCQ) and azithromycin (AZ) has received intense worldwide attention. Even as the efficacy of this combination is under evaluation, clinicians have begun to use it largely. As these medications are known to prolong the QT interval, we analyzed serial electrocardiograms recorded in patients ...

Review on the coronavirus disease (COVID-19) pandemic: its outbreak and current status.
https://doi.org/10.1111/ijcp.13637
International Journal of Clinical Practice; Almaghaslah D, Kandasamy G et. al.

Aug 4th, 2020 - In late December 2019 and on 1st January 2020, the coronavirus (COVID-19) infecting humans was first identified in Wuhan, Hubei Province, China. Later cases have also been confirmed worldwide. Coronaviruses are RNA viruses that are phenotypically and genotypically diverse. Globally, as of 6th April 2020, laboratory confirmed cases of COVID-19 reported to the World Health Organization (WHO) amou...

Inpatient Care during the COVID-19 Pandemic: A Survey of Italian Physicians.
https://doi.org/10.1159/000509007
Respiration; International Review of Thoracic Diseases; Attanasi M, Pasini S et. al.

Aug 4th, 2020 - Coronavirus disease 2019 (COVID-19) is a potentially fatal disease that is of great global public health concern. We explored the clinical management of inpatients with COVID-19 in Italy. A self-administered survey was sent by email to Italian physicians caring for adult patients with COVID-19. A panel of experts was selected according to their clinical curricula and their responses were analyz...

Medication therapy strategies for the coronavirus disease 2019 (COVID-19): recent progr...
https://doi.org/10.1080/17512433.2020.1805315
Expert Review of Clinical Pharmacology; Yang X, Liu Y et. al.

Aug 3rd, 2020 - The coronavirus disease 2019 (COVID-19) pandemic has spread globally since it outbroke in December 2019. The urgent pandemic presents an unprecedented challenge to develop and identify effective medication therapy strategies to combat the COVID-19. Here, we summarized and evaluated the current treatment drugs and regimens, and put forward the treatment recommendations, including using the poten...

Antirheumatic Disease Therapies for the Treatment of COVID-19: A Systematic Review and ...
https://doi.org/10.1002/art.41469
Arthritis & Rheumatology (Hoboken, N.J.); Putman M, Chock YPE et. al.

Aug 2nd, 2020 - Antirheumatic disease therapies have been used to treat coronavirus disease 2019 (COVID-19) and its complications. We conducted a systematic review and meta-analysis to describe the current evidence. A search of published and preprint databases in all languages was performed. Included studies described one or more relevant clinical outcomes in five or more people who were infected with SARS-CoV...

In silico Study of Azithromycin, Chloroquine and Hydroxychloroquine and their Potential...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7390782
International Journal of Antimicrobial Agents; Braz HLB, de Moraes Silveira JA et. al.

Aug 1st, 2020 - The coronavirus disease 19 (COVID-19) is a highly transmissible viral infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clinical trials have reported an improved outcome resulting from effective reduction or absence of viral load when patients were treated with chloroquine or hydroxychloroquine. In addition, these drugs had their effects improved by simultaneous ...

nImpact of medical care including anti-infective agents use on the prognosis of COVID-1...
https://doi.org/10.1016/j.ijantimicag.2020.106129
International Journal of Antimicrobial Agents; Davido B, Boussaid G et. al.

Aug 1st, 2020 - Interest of anti-infective agents in COVD-19 showed discrepant results. However, there is no evaluation about the impact in changes of practices on the prognosis over time. Single center, retrospective study, conducted from March 5th to April 25th 2020, in adults hospitalized in a medicine ward for a COVID-19. Patient characteristics were compared between 2 periods (before/after March 19th) con...

Drug treatments for covid-19: living systematic review and network meta-analysis.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7390912
BMJ (Clinical Research Ed.); Siemieniuk RA, Bartoszko JJ et. al.

Jul 31st, 2020 - To compare the effects of treatments for coronavirus disease 2019 (covid-19). Living systematic review and network meta-analysis. US Centers for Disease Control and Prevention COVID-19 Research Articles Downloadable Database, which includes 25 electronic databases and six additional Chinese databases to 20 July 2020. Randomised clinical trials in which people with suspected, probable, or confir...

Anti-Inflammatory Properties of Drugs Used to Control COVID-19 and their Effects on the...
https://doi.org/10.18433/jpps31346
Journal of Pharmacy & Pharmaceutical Sciences : a Publication of the Canadian Society for Pharmaceutical Sciences, Societe Canadienne Des Sciences Pharmaceutiques; Gilzad-Kohan H, Jamali F

Jul 31st, 2020 - COVID-19 infection is associated with systemic inflammation, and sometimes hyperinflammatory responses with cytokine storm. This plays a major role in COVID-19 severity and poor disease prognosis, even death. Higher levels of inflammatory hallmarks including C-reactive protein, ferritin, D-dimers, and cytokines such as interleukin (IL) -6, IL-10 and tumor necrosis factor- α (TNF-α) have been re...

Hydroxychloroquine Alternatives for Chronic Disease: Response to a Growing Shortage Ami...
https://doi.org/10.1177/0897190020942658
Journal of Pharmacy Practice; Husayn SS, Brown JD et. al.

Jul 30th, 2020 - With the emergence of a novel severe acute respiratory syndrome coronavirus, investigators worldwide are scrambling to identify appropriate treatment modalities, develop accurate testing, and produce a vaccine. To date, effective treatment remains elusive. Chloroquine phosphate and hydroxychloroquine sulfate (HCQ), well-known antimalarial drugs effective in the treatment of systemic lupus eryth...

Description of 3 patients with myasthenia gravis and COVID-19.
https://doi.org/10.1016/j.jns.2020.117053
Journal of the Neurological Sciences; Rein N, Haham N et. al.

Jul 30th, 2020 - The COVID-19 pandemic presents two main concerns for patients with myasthenia gravis (MG); chronic immunosuppression may put them at greater risk, and some proposed treatments for COVID-19 could cause MG exacerbation. We present three patients with generalized seropositive MG who developed COVID-19. All patients had a favorable outcome, with only one patient experiencing exacerbation. In this c...

Evaluation of electrocardiographic ventricular repolarization variables in patients wit...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373019
Journal of Electrocardiology; Yenerçağ M, Arslan U et. al.

Jul 30th, 2020 - Coronavirus disease 2019 (COVID-19) is a newly recognized infectious disease that has spread rapidly. COVID-19 has been associated with a number of cardiovascular complications, including arrhythmias. The mechanism of ventricular arrhythmias in patients with COVID-19 is uncertain. The aim of the present study was to evaluate the ventricular repolarization by using the Tp-e interval, QT dispersi...

Response to: 'COVID-19 among Malaysian patients with systemic lupus erythematosus on hy...
https://doi.org/10.1136/annrheumdis-2020-218173
Annals of the Rheumatic Diseases; Mathian A, Amoura Z

Jul 30th, 2020 - Response to: 'COVID-19 among Malaysian patients with systemic lupus erythematosus on hydroxychloroquine' by Teh et al.|2020|Mathian A,Amoura Z,|

Superior Mesenteric Artery Thrombosis and Acute Intestinal Ischemia as a Consequence of...
https://doi.org/10.12659/AJCR.925753
The American Journal of Case Reports; Cheung S, Quiwa JC et. al.

Jul 29th, 2020 - BACKGROUND The novel COVID-19 disease caused by the SARS-CoV-2 virus is a highly infectious disease that originated in Wuhan, China, and has rapidly spread throughout the world. In addition to respiratory complications, the virus has also been implicated in damage to other organ systems as well as coagulopathy. The present report describes the first presumptive case of COVID-19-associated acute...

Association between treatment with colchicine and improved survival in a single-centre ...
https://doi.org/10.1136/annrheumdis-2020-217712
Annals of the Rheumatic Diseases; Scarsi M, Piantoni S et. al.

Jul 29th, 2020 - The outbreak of COVID-19 posed the issue of urgently identifying treatment strategies. Colchicine was considered for this purpose based on well-recognised anti-inflammatory effects and potential antiviral properties. In the present study, colchicine was proposed to patients with COVID-19, and its effects compared with 'standard-of-care' (SoC). In the public hospital of Esine, northern Italy, 14...

Successful recovery of recurrence of positive SARS-CoV-2 RNA in COVID-19 patient with s...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7385201
Clinical Rheumatology; He F, Luo Q et. al.

Jul 29th, 2020 - COVID-19 has become a global concern. A large number of reports have explained the clinical characteristics and treatment strategies of COVID-19, but the characteristics and treatment of COVID-19 patient with systemic lupus erythematosus (SLE) are still unclear. Here, we report the clinical features and treatment of the first SLE patient with confirmed COVID-19 pneumonia. This was a 39-year-old...

OUTBREAK of novel corona virus disease (COVID-19): Antecedence and aftermath.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7381902
European Journal of Pharmacology; Awasthi A, Vishwas S et. al.

Jul 29th, 2020 - Outbreak of Coronavirus disease 2019 (COVID-19) started in mid of December 2019 and spread very rapidly across the globe within a month of its outbreak. Researchers all across the globe started working to find out its possible treatments. However, most of initiatives taken were based on various hypotheses and till date no successful treatments have been achieved. Some strategies adopted by Chin...

Brief Review of Chloroquine and Hydroxychloroquine Toxicity and Management.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7390560
The Western Journal of Emergency Medicine; Lebin JA, LeSaint KT

Jul 29th, 2020 - As of April 21, 2020, more than 2.5 million cases of coronavirus disease 2019 (COVID-19), caused by the SARS-CoV-2 virus, have been reported in 210 countries and territories, with the death toll at 171,810. Both chloroquine and hydroxychloroquine have gained considerable media attention as possible therapies, resulting in a significant surge in demand. In overdose, both medications can cause se...

Abnormal Liver Tests in COVID-19: A Retrospective Observational Cohort Study of 1827 Pa...
https://doi.org/10.1002/hep.31487
Hepatology (Baltimore, Md.); Hundt MA, Deng Y et. al.

Jul 28th, 2020 - The COVID-19 pandemic, caused by the SARS-CoV-2 virus, is associated with significant morbidity and mortality due to pneumonia, acute respiratory distress syndrome (ARDS) and multiorgan failure. Liver injury has been reported as a non-pulmonary manifestation of COVID-19 but characterization of liver test abnormalities and their association with clinical outcomes is incomplete. We conducted a re...

Interactions Between Remdesivir, Ribavirin, Favipiravir, Galidesivir, Hydroxychloroquin...
https://doi.org/10.1166/jnn.2020.18955
Journal of Nanoscience and Nanotechnology; Silva Arouche TD, Reis AF et. al.

Jul 27th, 2020 - We started a study on the molecular docking of six potential pharmacologically active inhibitors compounds that can be used clinically against the COVID-19 virus, in this case, remdesivir, ribavirin, favipiravir, galidesivir, hydroxychloroquine and chloroquine interacting with the main COVID-19 protease in complex with a COVID-19 N3 protease inhibitor. The highest values of affinity energy foun...